Aegerion Pharmaceuticals, an emerging biopharmaceutical company, has appointed Mark Fitzpatrick as chief financial officer (CFO). He brings over 15 years of financial management experience in both public and private companies.
Most recently Fitzpatrick was vice president, CFO and assistant secretary at Proteon Therapeutics. Prior to this, he was vice president and CFO, treasurer and assistant secretary with RenaMed Biologics. He also held CFO positions with Dynogen Pharmaceuticals, WorldStreet Corporation and Diacrin. He previously was a senior auditor with Arthur Andersen & Co.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.